Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) in Patients With Hormone Receptor-Positive Cancers With Recurrence Scores greater than or equal to 25

Trial Profile

Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) in Patients With Hormone Receptor-Positive Cancers With Recurrence Scores greater than or equal to 25

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Docetaxel (Primary) ; Cyclophosphamide
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Nov 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov record
    • 05 Oct 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
    • 30 Apr 2015 Planned End Date changed from 1 Sep 2015 to 1 Sep 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top